13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001822947
Total reported value
$113.1M
$113.1M
24 檔
47.3%
In Q2 2025, Ally Bridge Group's U.S. equity holdings reached a combined market value of $113.1M, distributed across 24 disclosed stock positions.
Ally Bridge Group executed strategic sector rebalancing during Q2 2025, establishing 9 new positions while fully exiting 13 holdings and trimming 5 positions.
In terms of portfolio concentration, the top 5 core holdings (including VRNA, SLNOEUR, LENZ) accounted for 47.3% of total reported equity market value during Q2 2025.
Top New Position Initiated
LENZ
市值: $10.1M
Top Position Liquidated / Trimmed
SWTXUSD
前期市值: $12.4M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 12.65% | — | +15.56% | |
| 2 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 12.47% | -10.82% | EXIT | |
| 3 | LENZ | Lenz Therapeutics Inc | Stock-Other | 8.37% | — | — | |
| 4 | ✓ | Merus N V | Stock-Other | 6.14% | — | +79.99% | |
| 5 | ✓ | Ultragenyx Pharmaceutical In | Stock-Other | 4.84% | — | — | |
| 6 | ELVN | Enliven Therapeutics Inc | Stock-Other | 4.70% | — | +65.75% | |
| 7 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 4.10% | — | — | |
| 8 | REPL | Replimune Group Inc | Stock-Other | 4.09% | -1.53% | EXIT | |
| 9 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 4.08% | -4.58% | EXIT | |
| 10 | INSM | Insmed Inc | Stock-Healthcare | 4.00% | — | -43.94% | |
| 11 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 3.92% | — | +86.13% | |
| 12 | GERN | Geron CORP | Stock-Other | 3.81% | — | +58.10% | |
| 13 | CMPS | Compass Pathways PLC | Stock-Other | 3.46% | -4.67% | EXIT | |
| 14 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 3.21% | — | +20.94% | |
| 15 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 3.14% | — | — | |
| 16 | SLDB | Solid Biosciences Inc | Stock-Other | 2.93% | -2.20% | — | |
| 17 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 2.90% | — | — | |
| 18 | PRAX | Praxis Precision Medicines I | Stock-Other | 2.83% | -8.54% | EXIT | |
| 19 | TECX | Tectonic Therapeutic Inc | Stock-Other | 2.71% | — | +23.79% | |
| 20 | KRRO | Korro Bio Inc | Stock-Other | 1.60% | — | +158.23% | |
| 21 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 1.27% | +1.03% | — | |
| 22 | ATYR | Atyr Pharma Inc | Stock-Other | 1.21% | — | -62.97% | |
| 23 | MNPR | Monopar Therapeutics Inc | Stock-Other | 1.03% | — | — | |
| 24 | PMNEUR | Promis Neurosciences Inc | Stock-Other | 0.54% | — | -10.12% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | LENZ | Lenz Therapeutics Inc | +8.4% | NEW | New buy |
| 2 | ✓ | Ultragenyx Pharmaceutical In | +4.8% | NEW | New buy |
| 3 | SLNOEUR | Soleno Therapeutics Inc | +4.7% | +48.46% | Add |
| 4 | VRNA | Verona Pharma PLC - Adr | +4.7% | +15.56% | Add |
| 5 | ORIC | Oric Pharmaceuticals Inc | +4.1% | NEW | New buy |
| 6 | REPL | Replimune Group Inc | +4.1% | NEW | New buy |
| 7 | CMPS | Compass Pathways PLC | +3.5% | NEW | New buy |
| 8 | ✓ | Merus N V | +3.2% | +79.99% | Add |
| 9 | RNAGBP | Avidity Biosciences Inc | +3.1% | NEW | New buy |
| 10 | SLDB | Solid Biosciences Inc | +2.9% | NEW | New buy |
| 11 | LXEO | Lexeo Therapeutics Inc | +2.9% | NEW | New buy |
| 12 | BRD1EUR | Mind Medicine Mindmed Inc | +1.9% | +86.13% | Add |
| 13 | ELVN | Enliven Therapeutics Inc | +1.7% | +65.75% | Add |
| 14 | MNPR | Monopar Therapeutics Inc | +1% | NEW | New buy |
| 15 | GERN | Geron CORP | +0.9% | +58.10% | Add |
| 16 | KRRO | Korro Bio Inc | +0.7% | +158.23% | Add |
| 17 | TECX | Tectonic Therapeutic Inc | +0.6% | +23.79% | Add |
| 18 | 260 | Centessa Pharmaceuticals-adr | +0.1% | +20.94% | Add |
| 19 | WHWK | Whitehawk Therapeutics Inc | 0% | — | Unchanged |
| 20 | PMNEUR | Promis Neurosciences Inc | -0.4% | -10.12% | Trim |
| 21 | PRAX | Praxis Precision Medicines I | -0.4% | -15.38% | Trim |
| 22 | CNTX | Context Therapeutics Inc | -0.6% | EXIT | Sold out |
| 23 | TYRA | Tyra Biosciences Inc | -0.9% | EXIT | Sold out |
| 24 | ATYR | Atyr Pharma Inc | -0.9% | -62.97% | Trim |
| 25 | DNTH | Dianthus Therapeutics Inc | -1.3% | EXIT | Sold out |
| 26 | TARS | Tarsus Pharmaceuticals Inc | -1.8% | -5.28% | Trim |
| 27 | INSM | Insmed Inc | -1.9% | -43.94% | Trim |
| 28 | ✓ | Edgewise Therapeutics Inc | -2% | EXIT | Sold out |
| 29 | JANX | Janux Therapeutics Inc | -2% | EXIT | Sold out |
| 30 | EWTX | Edgewise Therapeutics Inc | -2% | EXIT | Sold out |
| 31 | XENE | Xenon Pharmaceuticals Inc | -2.1% | EXIT | Sold out |
| 32 | CGON | Cg Oncology Inc | -2.9% | EXIT | Sold out |
| 33 | TRVI | Trevi Therapeutics Inc | -3.9% | EXIT | Sold out |
| 34 | ✓ | Axsome Therapeutics Inc | -5.3% | EXIT | Sold out |
| 35 | 2655787D | Blueprint Medicines CORP | -5.9% | EXIT | Sold out |
| 36 | AXSM | Axsome Therapeutics Inc | -7.6% | EXIT | Sold out |
| 37 | SWTXUSD | Springworks Therapeutics Inc | -11.2% | EXIT | Sold out |
According to official SEC Form 13F filings, Ally Bridge Group reported a total U.S. public equity portfolio value of $113.1M across 24 disclosed positions in Q2 2025.
During Q2 2025, Ally Bridge Group's top holdings by market value included VRNA (12.7%)、SLNOEUR (12.5%)、LENZ (8.4%). The largest single position, VRNA, represented 12.7% of total portfolio value.
In Q2 2025, Ally Bridge Group made 36 total portfolio adjustments, initiating 9 new buys, adding to 9 positions, trimming 5 holdings, and fully liquidating 13 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.